{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T00:38:09Z","timestamp":1791506289238,"version":"4.3.4"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Anti-GQ1b antibody syndrome is a spectrum of autoimmune neurological disorders that includes Miller Fisher syndrome, Guillain-Barr\u00e9 syndrome (GBS) with ophthalmoplegia, Bickerstaff brainstem encephalitis, and acute ophthalmoplegia without ataxia. These conditions are characterized by the presence of immunoglobulin G (IgG) antibodies targeting GQ1b gangliosides. The coexistence of anti-GQ1b antibody syndrome and myasthenia gravis (MG) is rare and presents diagnostic and therapeutic challenges. We report the case of an 84-year-old Japanese man with overlapping features of both disorders, describing his clinical course and response to add-on treatment with the neonatal Fc receptor antagonist efgartigimod. He presented with fever and diarrhea, followed by acute limb weakness. He was initially suspected of having had a stroke but was later diagnosed with GBS based on areflexia, anti-ganglioside antibody positivity, and nerve conduction abnormalities. Intravenous immunoglobulin therapy was initiated but his condition worsened, leading to respiratory failure and mechanical ventilation. Subsequently, bilateral ptosis and eye movement dysfunction emerged, prompting the consideration of MG. Anti-acetylcholine receptor antibodies and tensilon test results were positive and high-dose methylprednisolone was administered, resulting in partial improvement. Plasmapheresis was performed, but profound limb weakness and respiratory failure persisted; intravenous efgartigimod was thus introduced. Remarkably, the patient\u2019s respiratory function improved within 7 days, leading to ventilator weaning, and his limb weakness showed notable recovery. After a second cycle of efgartigimod, the patient regained speech and independent mobility, allowing transfer to a rehabilitation facility. His case underscores the diagnostic complexity of overlapping anti-GQ1b antibody syndrome and MG, and it highlights the therapeutic potential of efgartigimod in treating refractory cases of overlapping autoimmune neuromuscular syndromes. Given the rapid efficacy of efgartigimod for improving both respiratory and motor functions in this case, it is apparent that efgartigimod can be a valuable therapeutic option in complex neuromuscular autoimmune conditions.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1605985","type":"journal-article","created":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T05:22:55Z","timestamp":1749532975000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Case Report: Therapeutic effect of efgartigimod in refractory anti-GQ1b antibody syndrome coexisting with myasthenia gravis"],"prefix":"10.3389","volume":"16","author":[{"given":"Keiko","family":"Watanabe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiya","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akane","family":"Kanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Kakinuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Yano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuta","family":"Kinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.1123","article-title":"Expanding clinical spectrum of anti-GQ1b antibody syndrome: A review","volume":"81","author":"Lee","year":"2024","journal-title":"JAMA Neurol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2021.814453","article-title":"Case report: A patient diagnosed with miller fisher syndrome and myasthenia gravis at the same time","volume":"12","author":"Chen","year":"2022","journal-title":"Front Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00823","article-title":"Ophthalmoplegia due to miller fisher syndrome in a patient with myasthenia gravis","volume":"10","author":"Brusa","year":"2019","journal-title":"Front Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2008.08.019","article-title":"The co-occurrence of serologically proven myasthenia gravis and miller fisher\/guillain barre overlap syndrome: A case report","volume":"276","author":"Lau","year":"2009","journal-title":"J Neurol Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinph.2021.02.013","article-title":"The value of sensory nerve conduction studies in the diagnosis of guillain-barre syndrome","volume":"132","author":"Freiha","year":"2021","journal-title":"Clin Neurophysiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1062567","article-title":"Case report: isolated facial and trigeminal nerve palsy without ataxia in anti-GQ1b antibody syndrome secondary to mycoplasma pneumonia","volume":"13","author":"Deng","year":"2022","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000529463","article-title":"Principles of therapeutic apheresis in neurological disease","volume":"50","author":"Strasser","year":"2023","journal-title":"Transfus Med Hemother"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.1389-22","article-title":"A case with anti-ganglioside antibodies showing multiple cranial nerve palsies detected on gadolinium-enhanced magnetic resonance imaging","volume":"62","author":"Suzuki","year":"2023","journal-title":"Intern Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.56064","article-title":"Miller-fisher syndrome following influenza a infection","volume":"16","author":"Mitsuhashi","year":"2024","journal-title":"Cureus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2169\/internalmedicine.4667-24","article-title":"Subacute upper motor neuron dysfunction possibly associated with the anti-GM1 autoantibody: A case report","author":"Okubo","year":"","journal-title":"Internal Med. in press"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/braincomms\/fcac306","article-title":"Complement inhibition prevents glial nodal membrane injury in a GM1 antibody-mediated mouse model","volume":"4","author":"Campbell","year":"2022","journal-title":"Brain Commun"},{"key":"B12","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3988\/jcn.2014.10.2.94","article-title":"Prevalence of anti-ganglioside antibodies and their clinical correlates with guillain-barr\u00e9 Syndrome in Korea: A nationwide multicenter study","volume":"10","author":"Kim","year":"2014","journal-title":"J Clin Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v12.i31.6500","article-title":"Miller fisher syndrome with positive anti-GQ1b\/GT1a antibodies associated with covid-19 infection: A case report","volume":"12","author":"Wei","year":"2024","journal-title":"World J Clin cases"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.24252","article-title":"Neurologic sequela of covid-19: guillain-barre syndrome following johnson & Johnson covid-19 vaccination","volume":"14","author":"Carranza","year":"2022","journal-title":"Cureus"},{"key":"B15","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1620\/tjem.2023.J019","article-title":"A case of miller fisher syndrome with cerebellar hypoperfusion","volume":"260","author":"Sumi","year":"2023","journal-title":"Tohoku J Exp Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/cen3.12739","article-title":"The Japanese clinical guidelines 2022 for myasthenia gravis and lambert\u2013eaton myasthenic syndrome","volume":"14","author":"Murai","year":"2023","journal-title":"Clin Exp Neuroimmunology"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2023-255782","article-title":"Burkholderia-associated polymyositis","volume":"17","author":"Kumar","year":"2024","journal-title":"BMJ Case Rep"},{"key":"B18","doi-asserted-by":"crossref","DOI":"10.1055\/s-2004-829594","article-title":"Myasthenia Gravis: Diagnosis","volume-title":"Seminars in neurology","author":"Meriggioli","year":"2004"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1007\/s00415-024-12443-9","article-title":"Anti-neurofascin-155 antibody mediated a distinct phenotype of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/jns.12583","article-title":"Evidence for spontaneous regulation of the humoral igm anti-gm1 autoimmune response by IgG antibodies in multifocal motor neuropathy patients","volume":"28","author":"Di Egidio","year":"2023","journal-title":"J Peripher Nerv Syst"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2008.08.011","article-title":"Current and future standards in treatment of myasthenia gravis","volume":"5","author":"Gold","year":"2008","journal-title":"Neurotherapeutics"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1405.038","article-title":"IVIG treatment for myasthenia gravis: effectiveness, limitations, and novel therapeutic strategies","volume":"1132","author":"Zinman","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000200107","article-title":"High and persistent anti-gm1 antibody titers are associated with poor clinical recovery in guillain-barre syndrome","volume":"10","author":"Thomma","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(97)12308-X","article-title":"Guillain-barre syndrome","volume":"352","author":"Hahn","year":"1998","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.2005.00374.x","article-title":"Myasthenia gravis: clinical, immunological, and therapeutic advances","volume":"111","author":"Romi","year":"2005","journal-title":"Acta Neurol Scand"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-006-0366-x","article-title":"Temporal coincidence between aman type of GBS and myasthenia gravis","volume":"254","author":"Kraus","year":"2007","journal-title":"J Neurol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/mus.10349","article-title":"IgG from patients with guillain-barre syndrome interact with nicotinic acetylcholine receptor channels","volume":"27","author":"Krampfl","year":"2003","journal-title":"Muscle Nerve"},{"key":"B29","article-title":"Concurrent guillain-barre syndrome and myasthenia gravis: the first case in Taiwan","volume":"18","author":"Kung","year":"2009","journal-title":"Acta Neurol Taiwan"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007719","article-title":"Current treatment practice of guillain-barre syndrome","volume":"93","author":"Verboon","year":"2019","journal-title":"Neurology"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1321058","article-title":"Case report: recovery from refractory myasthenic crisis to minimal symptom expression after add-on treatment with efgartigimod","volume":"15","author":"Watanabe","year":"2024","journal-title":"Front Neurol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911","article-title":"Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1177\/17562864251314746","article-title":"Sequential administration of efgartigimod shortened the course of guillain-barre syndrome: A case series","volume":"18","author":"Chen","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12321-4","article-title":"Efgartigimod in the treatment of guillain-barre syndrome","volume":"271","author":"Zhang","year":"2024","journal-title":"J Neurol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000040700","article-title":"Resolution of acute motor axonal neuropathy in a patient after treatment with efgartigimod: A case report","volume":"103","author":"Zhou","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B36","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1007\/s00415-023-11970-1","article-title":"Efgartigimod beyond myasthenia gravis: the role of FcRn-targeting therapies in stiffperson syndrome","volume":"271","author":"Di Stefano","year":"2024","journal-title":"J Neurol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27341","article-title":"Myasthenia gravis exacerbation in association with antibody overshoot following plasmapheresis","volume":"64","author":"Ching","year":"2021","journal-title":"Muscle Nerve"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1605985\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T05:22:56Z","timestamp":1749532976000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1605985\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,10]]},"references-count":37,"alternative-id":["10.3389\/fimmu.2025.1605985"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1605985","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,10]]},"article-number":"1605985"}}